Rate Control Agents for Atrial Fibrillation

Selection Algorithm Based on Cardiac Function

The European Society of Cardiology recommends beta-blockers or non-dihydropyridine calcium channel blockers as first-line agents for rate control in atrial fibrillation, with the choice primarily determined by left ventricular ejection fraction (LVEF) 1, 2
For patients with LVEF ≥40%, the American College of Cardiology suggests first-line options including beta-blockers, such as metoprolol, and non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil 3, 4
The American College of Cardiology recommends using the smallest dose of beta-blocker to achieve rate control as first-line therapy for patients with LVEF <40% or heart failure, and avoiding non-dihydropyridine calcium channel blockers due to negative inotropic effects 1, 2

The European Society of Cardiology recommends an initial target heart rate of <110 bpm at rest 1, 2
The American College of Cardiology suggests aiming for 60-80 bpm at rest and 90-115 bpm during moderate exercise for optimal control 6, 5

The American College of Cardiology advises avoiding diltiazem and verapamil in patients with heart failure with reduced ejection fraction (LVEF ≤40%), AV block greater than first degree without pacemaker, Wolff-Parkinson-White syndrome with AF, and hypotension 6
The American College of Cardiology recommends avoiding beta-blockers in patients with severe bradycardia, second or third-degree AV block without pacemaker, decompensated heart failure, and active asthma 3, 4, 5

The American College of Cardiology suggests digoxin should only be used as a second-line agent because it is effective only for rate control at rest, not during exercise, and is most appropriate for physically inactive elderly patients, add-on therapy when beta-blockers or calcium channel blockers alone are insufficient, and patients with heart failure as adjunctive therapy 7, 8, 1, 2, 3, 4

The European Society of Cardiology recommends adding digoxin to the initial beta-blocker or calcium channel blocker if monotherapy fails to achieve target heart rate 1, 2
The American College of Cardiology suggests combinations of digoxin plus diltiazem, atenolol, or betaxolol are effective at rest and with exercise 8

The European Society of Cardiology notes that beta-blockers do not reduce all-cause mortality in AF patients with heart failure with reduced ejection fraction (HR 0.97; 95% CI 0.83-1.14), but are still recommended based on symptomatic improvement, lack of harm, and good tolerability 1, 2